Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 1.00 |
| ▸ | HTR1D | P28221 | 5/20 | 1.00 |
| ▸ | HTR7 | P34969 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR5A | P47898 | 4/20 | 1.00 |
| ▸ | HTR1E | P28566 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633021 | 1.00 | HTR6 (1.00) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL11488806 | 0.87 | HTR6 (0.76) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL11518047 | 0.85 | HTR6 (0.74) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL8555235 | 0.84 | HTR1D (0.76) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL29389149 | 0.83 | HTR6 (1.00) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL2537573 | 0.83 | HTR6 (1.00) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL4231080 | 0.82 | HTR1D (0.74) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL4244966 | 0.82 | HTR1D (1.00) | HTR6HTR1DHTR7HTR1AHTR5A | |
| SCHEMBL6235393 | 0.82 | HTR6 (0.73) | HTR6HTR1DHTR7HTR1AHTR5A | |
| Hydrochloric Acid SCHEMBL7433474 | 0.81 | HTR1D (0.97) | HTR6HTR1DHTR7HTR1AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-6489488-B2 | SEROTONIN (5-HT) SUBTYPE 6 RECEPTOR (5-HT6); 3-(2-AMINOETHYL)INDOLE DERIVATIVES; DRUG SCREENING | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-12-03 | — | — | US | disclosed |
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-6403808-B1 | TREATING MENTAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-06-11 | — | — | US | disclosed |
| EP-1149078-A1 | SELECTIVE 5-HT 6? RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
| WO-2000034242-A1 | SELECTIVE 5-HT6 RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR6 1/4885HTR1D 16/4885HTR7 6/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR6 3/4885HTR1D 11/4885HTR7 2/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR6 10/4885HTR1D 12/4885HTR7 6/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR6 16/4885HTR1D 18/4885HTR7 35/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR6 8/4885HTR1D 1/4885HTR7 13/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR6 9/4885HTR1D 3/4885HTR7 13/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR6 2/4885HTR1D 7/4885HTR7 10/4885 |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR6 1/4885HTR1D 16/4885HTR7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.